Famotidine vs Cimetidine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Histamine-2 Receptor Antagonist

Famotidine

Brand: Pepcid

First FDA approval: 2001-03-15

Histamine-2 Receptor Antagonist

Cimetidine

First FDA approval: 1994-05-17

Lowest NADACAcquisition cost floor across all NDCs

$0.030Per unit

$0.205Per unit

Average NADACAcross all dosage forms and strengths

$0.063Up to $0.492

$0.414Up to $0.794

Generic manufacturersActive ANDA holders — FDA Orange Book

3463 total ANDAs filed

722 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$257.1MFull year

$9.0MFull year

Part D claims (CY24)Total fills, all strengths

21.4M7.1M beneficiaries

151K46K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$12Per claim, all NDCs

$59Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes34 manufacturers

Yes7 manufacturers